Rabbit small intestine does not contain an annexin II/caveolin 1 complex as a target for 2-azetidinone cholesterol absorption inhibitors.
Intestinal cholesterol absorption is specifically inhibited by the 2-azetidinone cholesterol absorption inhibitor ezetimibe. Photoreactive ezetimibe analogues specifically label a 145-kDa protein in the brush border membrane of enterocytes from rabbit small intestine identified as aminopeptidase N (CD13). In zebrafish and mouse small intestinal cytosol, a heterocomplex of M(r) 52 kDa between annexin II and caveolin 1 was suggested as a target of ezetimibe. In contrast, in the cytosol and brush border membrane vesicles (BBMV) from rabbit small intestine of control animals or rabbits treated with the nonabsorbable cholesterol absorption inhibitor AVE 5530, both annexin II and caveolin 1 were exclusively present as monomers without any heterocomplex formation. Upon immunoprecipitation with annexin II a 52-kDa band was observed after immunostaining with annexin II antibodies, whereas no staining of a 52-kDa band occurred with anti-caveolin 1 antibodies. Vice versa, a 52-kDa band obtained by immunoprecipitation with caveolin 1 antibodies did not stain with annexin II-antibodies. The intensity of the 52-kDa band was dependent on the amount of antibody and was also observed with anti-actin or anti-APN antibodies suggesting that the 52-kDa band is a biochemical artefact. After incubation of cytosol or BBMV with radioactively labelled ezetimibe analogues, no significant amounts of the ezetimibe analogues could be detected in the immunoprecipitate with caveolin-1 or annexin II antibodies. Photoaffinity labelling of rabbit small intestinal BBMV with ezetimibe analogues did not result in labelling of proteins being immunoreactive with annexin II, caveolin 1 or a 52-kDa heterocomplex. These findings indicate that the rabbit small intestine does not contain an annexin II/caveolin 1 heterocomplex as a target for ezetimibe.
Kramer
Werner
W
Sanofi-Aventis Deutschland GmbH, Industriepark Höchst/Gebäude G 879, 65926 Frankfurt am Main, Germany. Werner.Kramer@sanofi-aventis.com
Corsiero
Daniel
D
Girbig
Frank
F
Jähne
Gerhard
G
D000042:Absorption; D000818:Animals; D017306:Annexin A2 / Q000378:metabolism*; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D000924:Anticholesteremic Agents / Q000378:metabolism / Q000494:pharmacology*; D001384:Azetidines / Q000378:metabolism / Q000494:pharmacology*; D051242:Caveolin 1 / Q000378:metabolism*; D003593:Cytoplasm / Q000378:metabolism; D020895:Enterocytes / Q000378:metabolism; D000069438:Ezetimibe; D047468:Immunoprecipitation; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008871:Microvilli / Q000378:metabolism; D011817:Rabbits / Q000378:metabolism*
C116379:2-azetidinone; D017306:Annexin A2; D000906:Antibodies; D000924:Anticholesteremic Agents; D001384:Azetidines; D051242:Caveolin 1; D000069438:Ezetimibe